Cyramza® (ramucirumab) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	Email:	

Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____ Does patient have other coverage? ☐ Yes ☐ No
Group #: _____ If yes, provide ID#: _____ Carrier Name: _____
Insured: _____ Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:	Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.				
Address:	City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:	Office Contact Name:	Phone:			

Specialty *(Check one):* ☐ **Oncologist** ☐ **Hematologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other: _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for **Cyramza (ramucirumab):** Dose: _____ Frequency: _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required for all requests):

☐ **Colorectal cancer (CRC), including anal adenocarcinoma, appendiceal adenocarcinoma, colon cancer, and rectal cancer**
Please indicate the clinical setting in which the requested drug will be used: ☐ Advanced disease ☐ Metastatic disease ☐ Other
☐ Yes ☐ No Will the requested drug be used in combination with either FOLFIRI (fluorouracil, leucovorin, and irinotecan) or irinotecan?
→ Please select: ☐ Combination treatment with FOLFIRI (fluorouracil, leucovorin, and irinotecan)
☐ Combination treatment with irinotecan

☐ **Esophageal adenocarcinoma** ☐ **Esophagogastric Junction (EGJ) adenocarcinoma** ☐ **Gastro-esophageal junction (GEJ) adenocarcinoma or** ☐ **Gastric adenocarcinoma**
Please indicate the clinical setting in which the requested drug will be used:
☐ Unresectable locally advanced disease ☐ Recurrent disease ☐ Metastatic disease ☐ Other
☐ Yes ☐ No Is the patient a surgical candidate?
What is the place in therapy in which the requested drug will be used? ☐ First-line treatment ☐ Subsequent treatment
☐ Yes ☐ No Will the requested drug be used as a single agent?
→ ☐ Yes ☐ No Will the requested drug be used in combination with paclitaxel?
☐ Yes ☐ No Will the requested drug be used in combination with irinotecan with or without fluorouracil?

Continued on next page

Cyramza® (ramucirumab) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ **Hepatocellular carcinoma**

What is the place in therapy in which the requested drug will be used? ☐ First-line treatment ☐ Subsequent treatment

Please indicate the clinical setting in which the requested drug will be used: ☐ Progressive disease ☐ Other

☐ Yes ☐ No Will the requested drug be used as a single agent?

☐ Yes ☐ No ☐ Unknown Does the patient have an alpha fetoprotein (AFP) of greater than or equal to 400 ng/mL?

☐ **Mesothelioma**

Please indicate which of the following applies to the patient's disease:

☐ Pleural mesothelioma ☐ Pericardial mesothelioma ☐ Tunica vaginalis testis mesothelioma ☐ Other

What is the place in therapy in which the requested drug will be used? ☐ First-line treatment ☐ Subsequent treatment

☐ Yes ☐ No Will the requested drug be used in combination with gemcitabine?

☐ **Non-small cell lung cancer (NSCLC)**

Please indicate the clinical setting in which the requested drug will be used:

☐ Advanced disease ☐ Recurrent disease ☐ Metastatic disease ☐ Other

☐ Yes ☐ No Will the requested medication be used in combination with erlotinib?

→ ☐ Yes ☐ No Will the requested medication be used in combination with docetaxel?

What is the place in therapy in which the requested medication will be used? ☐ First-line treatment ☐ Subsequent treatment

→ ☐ Yes ☐ No ☐ Unknown Does the patient have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation positive disease?

For Continuation Requests (clinical documentation required for all requests):

Non-small cell lung cancer (NSCLC) only:

☐ Yes ☐ No Does the patient have T790M negative disease?

→ ☐ Yes ☐ No Is there evidence of unacceptable toxicity or disease progression while on the current regimen?

→ ☐ Yes ☐ No Is there evidence of unacceptable toxicity while on the current regimen?

For all other continuation requests:

☐ Yes ☐ No Is there evidence of unacceptable toxicity or disease progression while on the current regimen?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.